Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.48 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.48 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.48 |
| ▸ | BMP1 | P13497 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600575 | 1.00 | ABCB1 (0.48) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL1601815 | 0.96 | ABCB1 (0.48) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL1603132 | 0.96 | ABCB1 (0.48) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL1603230 | 0.93 | ABCB1 (0.48) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL1602914 | 0.93 | ABCB1 (0.48) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL7970111 | 0.93 | ABCB1 (0.48) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL1600704 | 0.90 | ABCB1 (0.49) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL1601916 | 0.90 | ABCB1 (0.49) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL1601311 | 0.90 | ABCB1 (0.52) | ABCB1KCNE1KCNQ1KCNH2SCN5A | |
| SCHEMBL1602720 | 0.90 | ABCB1 (0.52) | ABCB1KCNE1KCNQ1KCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919523-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090042973-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-7442718-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1637518-A2 | Inhibitors of aspartyl protease | Vertex Pharmaceuticals Incorporated (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20040127488-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2004-07-01 | — | — | US | disclosed |
| US-6617350-B2 | Sulfonamides which are aspartyl protease inhibitors; well suited for inhibiting HIV-1 and HIV-2 protease activity | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-09 | — | — | US | disclosed |
| US-20020198388-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-12-26 | — | — | US | disclosed |
| US-6319946-B1 | BENZODIOXOLYLSULFONAMIDES; INHIBITING HIV-1 AND HIV-2 PROTEASE ACTIVITY | VERTEX PHARMACEUTICALS INCORPORATED | 2001-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042973-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | ABCB1 628/4885KCNE1 3515/4885KCNQ1 3090/4885 |
| US-20040127488-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | ABCB1 628/4885KCNE1 3515/4885KCNQ1 3090/4885 |
| US-20020198388-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | ABCB1 628/4885KCNE1 3515/4885KCNQ1 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.